Tenpoint Therapeutics secures $235 million through Series B financing led by Janus Henderson to accelerate commercialization of YUVEZZI™.
PRIVATEJan 29, 2026
Amount Raised
$235 Million
Round Type
Series B
SeattleBiotechnologyHealth CareTherapeutics
Investors
AdBioWilleAd BioSofinnova PartnersEQT Life SciencesBritish Business BankHillhouseEQT NexusF PrimeEight RoadsQiming Venture Partners USAJanus Henderson
Description
Tenpoint Therapeutics, a commercial biotechnology company, has raised $235 million through Series B financing and a credit facility. The Series B round saw participation from prominent investors including Janus Henderson and EQT Nexus. The funding will support the launch of YUVEZZI™, the first dual-agent eye drop for presbyopia. CEO Henric Bjarke expressed confidence in the product's potential to meet the needs of millions affected by this condition.
Company Information
Company
Tenpoint Therapeutics
Location
Seattle, Washington, United States
About
Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. We are addressing the ultimate cause of vision loss by replacing diseased cells with healthy ones to permanently restore vision. Tenpoint’s global team is united by our passion for science and our commitment to patients.
Fundz sees it the moment Tenpoint Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
SeattleBiotechnologyHealth CareTherapeutics